Table 1.

Baseline characteristics of patients on temozolomide 3/11 schedule (n = 15).

Patient	Sex	Age (years)	Diagnosis	Previous treatment		Past adjuvant CT	Cycles	Reason for enrollment	KPS at start of TMZ 3/11	Diagnosis to start of TMZ 3/11 (months)
				Surgery	Radiotherapy
1	F	61	GBM	STR	IMRT + TMZ	TMZ 5/23	2	Stable disease, patients choice	90	7
2	F	35	GBM	B	IMRT + TMZ	TMZ 5/23	6	MRI disease progression	90	7
3	M	55	GBM	B	IMRT + TMZ	TMZ 5/23	1	Clinical progression	80	7
4	M	55	GBM	B	IMRT	TMZ 5/23	7	MRI disease progression	60	8
5	M	56	GBM	GTR	IMRT + TMZ	TMZ 5/23	11	MRI disease progression	80	11
6	M	57	GBM	B	IMRT + TMZ	None	–	Clinical progression	70	4
7	M	36	AA	B	IMRT + TMZ	TMZ 5/23	2	MRI disease progression	80	5
8	M	33	APXA	GTR	IMRT + TMZ	TMZ 5/23	3	MRI disease progression	80	12
9	M	33	GBM	B	IMRT	TMZ 5/23	12	MRI disease progression	80	16
10	M	49	GBM	STR	IMRT + TMZ	TMZ 5/23	2	MRI disease progression	90	7
11	M	53	GBM	B	IMRT + TMZ	TMZ 5/23	3	MRI disease progression	70	8
12	M	73	GBM	GTR	IMRT + TMZ	TMZ 5/23	3	MRI disease progression	90	6
13	M	63	GBM	GTR	IMRT + TMZ	TMZ 5/23	4	MRI disease progression	90	10
14	M	58	GBM	STR	IMRT + TMZ	None	–	MRI disease progression	80	3†
15	F	56	GBM	STR	IMRT + TMZ	TMZ 5/23	3	MRI disease progression	70	7

^†Fluorodeoxyglucose-PET-positive recurrent disease.

AA: Anaplastic astrocytoma; APXA: Anaplastic pleomorphic xanthoastrocytoma; B: Biopsy; CT: Chemotherapy; F: Female; GBM: Glioblastoma; GTR: Gross total resection; IMRT: Intensity modulated radiation therapy; KPS: Karnofsky performance status; M: Male; STR: Subtotal resection; TMZ: Temozolomide.